
Cipla Limited has informed the Exchange regarding a press release dated August 12, 2021, titled "Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol�� (Difluprednate Ophthalmic Emulsion 0.05%)".
Filed with NSE · · 3 pages · English
Cipla Ltd has issued a press release announcing the receipt of final approval for its generic version of Durezol from the US FDA. The product, Difluprednate Ophthalmic Emulsion, is indicated for treating inflammation and pain associated with ocular surgery and endogenous anterior uveitis.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Cipla Limited has informed the Exchange regarding a press release dated August 12, 2021, titled "Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol�� (Difluprednate Ophthalmic Emulsion 0.05%)".
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla